U.S. Regenerative Medicine Market Size & Share Report, 2033
The U.S. regenerative medicine market size was valued at USD 17.19 billion in 2023 and is projected to surpass around USD 80.74 billion by 2033, registering a CAGR of 16.73% over the forecast period of 2024 to 2033.
The growth can be attributed to factors such as increasing investments in the regenerative medicine domain and a growing focus on launching new centers for regenerative medicine. Moreover, the developments in gene therapy, cell therapy, and tissue-engineered products in the country are expected to fuel further competition.
U.S. accounted for over 55% of the global regenerative medicine market in 2023. Academic and medical centers are providing funding to improve the regenerative medicine sector in the country. For instance, in October 2022, Cedars-Sinai was granted a 5-year, USD 8 million funding from California’s stem cell agency to establish a new clinic to improve training and research in regenerative medicine. Due to easy access to data through genomic, proteomic, and Electronic Health Record (EHR) databases, numerous companies are investigating various cell-based therapies to aid in the treatment of previously untreatable conditions.
Furthermore, the growing demand for robust therapies to address the rising cancer prevalence is contributing to growth in clinical trial numbers. Moreover, leading firms are investigating and developing pipeline products for diabetes & neurological disorders, such as Parkinson’s & Alzheimer’s diseases, cancers, and cardiovascular diseases, including myocardial infarction, heart failure, and ischemic heart diseases. Hence, the rising prevalence of these diseases increased the investments to improve the treatment of regenerative medicines.
Technological advancements such as stem cells, tissue engineering, and nanotechnology have made regenerative medicines a highly lucrative field of science. For instance, the wide acceptance of cell-based therapies in orthopedic surgeries significantly contributed to the overall stem cell market revenue. This can be attributed to stem cells forming an integral part of therapies based on regenerative medicine. Stem cells have been proven to accelerate treatment outcomes, expanding their usage. This has created multiple potential avenues for stem cell therapies that span orthopedics and other specialties.
| Report Attribute | Details |
| Market Size in 2024 | USD 20.07 Billion |
| Market Size by 2033 | USD 80.74 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 16.73% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product, therapeutic category |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | AstraZeneca plc; F. Hoffmann-La Roche Ltd.; Integra Lifesciences Corp.; Astellas Pharma, Inc.; Cook Biotech, Inc.; Bayer AG; Pfizer, Inc.; Merck KGaA; Abbott; Vericel Corp.; Novartis AG; GlaxoSmithKline (GSK). |
The oncology segment held the largest market share of 31.15% in 2023. The increasing prevalence of cancer coupled with combinational approaches using stem cells, immunotherapy, and gene therapy is expected to influence segment growth over the forecast period. Moreover, companies are developing various cell-based and gene therapies for cancer. Furthermore, many government organizations and industrial companies are investing in cancer research & expansion of regenerative medicines, including cell & gene therapies.
The cardiovascular segment is expected to witness a considerable CAGR during the forecast period owing to increasing prevalence of Cardiovascular Diseases (CVD) and the rising demand for products to treat these disorders. In addition, advancements in regenerative medicines and cell-based therapies have accelerated growth of the segment. The companies are undertaking various strategies to expand their pipelines in this segment and promoting further growth.
The therapeutics segment held the largest market share of 75.19% in 2023. Over the years, geriatric population of U.S. has witnessed significant growth which resulted in a higher incidence of degenerative and age-related disorders. The rising prevalence of these disorders with unmet medical needs, such as diabetes, cancer, and NDs, including Age-related Macular Degeneration (AMD), has prompted researchers to create alternative treatment options such as cell therapy. Demand for such therapies is further anticipated to increase significantly owing to advances in stem & progenitor cell therapies and their high potential in treating a broad range of conditions.
The bank segment is expected to witness the fastest CAGR from 2024 to 2033 owing to its usage of large-scale collection, preparation, provision, research, and storage of stem cells. In recent years, the number of private cord blood banks has witnessed a rapid rise. This can be attributed to the availability of guidelines on using stem cells and umbilical cords for research purposes. Moreover, companies are undertaking various strategies to promote biobanking. The rapid adoption of private cord blood banking by people in the country is expected to significantly contribute to segment growth.
Some prominent U.S. regenerative medicine market companies include Vitrolife; AstraZeneca; F. Hoffmann-La Roche Ltd.; Integra LifeSciences: Astellas Pharma Inc.; COOK BIOTECH; Merck KGaA; Vericel Corporation; Novartis Pharmaceuticals Corporation; bluebird bio, Inc.; and Bristol-Myers Squibb Company. Key market companies are adopting multifaceted strategies to remain in competition in the ever-evolving market setting.
They are initiating strategic M&A activities, partnerships, and collaborations with other market players and academic institutions intending to exchange knowledge and accelerate innovations. In addition, key players are undertaking various strategies, such as collaborations with Contract Manufacturing Organizations (CMOs), to sustain their market position. These companies are also prioritizing regulatory navigation, to ensure on-time approvals and access to the market.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Regenerative Medicine market.
By Product
By Therapeutic Category
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Information analysis
1.2.2. Market formulation & data visualization
1.2.3. Data validation & publishing
1.3. Information Procurement
1.3.1. Primary Others
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Market Model
1.7. Objectives
1.7.1. Objective 1
1.7.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Presence of a strong pipeline and a large number of clinical trials
3.3.2. High economic impact of regenerative medicine
3.3.3. Emerging applications of gene therapy in regenerative medicine
3.3.4. Increasing government & private funding to support the development of regenerative medicine
3.3.5. Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
3.3.6. Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
3.3.7. Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
3.4. Market Restraint Analysis
3.4.1. High cost of treatment
3.4.2. Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
3.5. Business Environment Analysis
3.5.1. PESTEL Analysis
3.5.2. Porter’s Five Forces Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. U.S. Regenerative Medicine Market: Product Movement Analysis
4.2. Therapeutics
4.2.1. Therapeutics Market, 2021 - 2033
4.2.2. Primary Cell-Based Therapeutics
4.2.2.1. Primary Cell-Based Therapeutics Market, 2021 - 2033
4.2.2.2. Dermatology
4.2.2.2.1. Dermatology Market, 2021 - 2033
4.2.2.3. Musculoskeletal
4.2.2.3.1. Musculoskeletal Market, 2021 - 2033
4.2.2.4. Surgical
4.2.2.4.1. Surgical Market, 2021 - 2033
4.2.2.5. Dental
4.2.2.5.1. Dental Market, 2021 - 2033
4.2.2.6. Others
4.2.2.6.1. Others Market, 2021 - 2033
4.2.3. Stem Cell & Progenitor Cell-based therapeutics
4.2.3.1. Stem Cell & Progenitor Cell-based therapeutics Market, 2021 - 2033
4.2.3.2. Autologous
4.2.3.2.1. Autologous Market, 2021 - 2033
4.2.3.3. Allogenic
4.2.3.3.1. Allogenic Market, 2021 - 2033
4.2.3.4. Others
4.2.3.5. Others Market, 2021 - 2033
4.2.4. Cell-based Immunotherapies
4.2.4.1. Cell-based Immunotherapies Market, 2021 - 2033
4.2.5. Gene Therapies
4.2.5.1. Gene Therapies Market, 2021 - 2033
4.3. Tools
4.3.1. Tools Market, 2021 - 2033
4.4. Banks
4.4.1. Banks Market, 2021 - 2033
4.5. Services
4.5.1. Services Market, 2021 - 2033
Chapter 5. Therapeutic Category Business Analysis
5.1. U.S. Regenerative Medicine Market: Therapeutic Category Movement Analysis
5.2. Dermatology
5.2.1. Dermatology Market, 2021 - 2033
5.3. Musculoskeletal
5.3.1. Musculoskeletal Market, 2021 - 2033
5.4. Immunology & Inflammation
5.4.1. Immunology & Inflammation Market, 2021 - 2033
5.5. Oncology
5.5.1. Oncology Market, 2021 - 2033
5.6. Cardiovascular
5.6.1. Cardiovascular Market, 2021 - 2033
5.7. Ophthalmology
5.7.1. Ophthalmology Market, 2021 - 2033
5.8. Others
5.8.1. Others Market, 2021 - 2033
Chapter 6. Competitive Landscape
6.1. Company Categorization
6.2. Strategy Mapping
6.3. Company Market/Position Share Analysis, 2022
6.4. Company Profiles/Listing
6.4.1. AstraZeneca plc.
6.4.1.1. Overview
6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.1.3. Product Benchmarking
6.4.1.4. Strategic Initiatives
6.4.2. F. Hoffmann-La Roche Ltd.
6.4.2.1. Overview
6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.2.3. Product Benchmarking
6.4.2.4. Strategic Initiatives
6.4.3. Integra Lifesciences Corp.
6.4.3.1. Overview
6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.3.3. Product Benchmarking
6.4.3.4. Strategic Initiatives
6.4.4. Astellas Pharma, Inc.
6.4.4.1. Overview
6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.4.3. Product Benchmarking
6.4.4.4. Strategic Initiatives
6.4.5. Cook Biotech, Inc.
6.4.5.1. Overview
6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.5.3. Product Benchmarking
6.4.5.4. Strategic Initiatives
6.4.6. Bayer AG
6.4.6.1. Overview
6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.6.3. Product Benchmarking
6.4.6.4. Strategic Initiatives
6.4.7. Pfizer, Inc.
6.4.7.1. Overview
6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.7.3. Product Benchmarking
6.4.7.4. Strategic Initiatives
6.4.8. Merck KGaA
6.4.8.1. Overview
6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.8.3. Product Benchmarking
6.4.8.4. Strategic Initiatives
6.4.9. Abbott
6.4.9.1. Overview
6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.9.3. Product Benchmarking
6.4.9.4. Strategic Initiatives
6.4.10. Vericel Corp.
6.4.10.1. Overview
6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.10.3. Product Benchmarking
6.4.10.4. Strategic Initiatives
6.4.11. Novartis AG
6.4.11.1. Overview
6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.11.3. Product Benchmarking
6.4.11.4. Strategic Initiatives
6.4.12. GlaxoSmithKline
6.4.12.1. Overview
6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.12.3. Product Benchmarking
6.4.12.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers